Pfizer Roars to Record on Covid Vaccine, Treatment Successes
- FDA on Friday authorized booster shots for all adults
- Long-term sales opportunities underestimated, BMO analyst says
This article is for subscribers only.
Pfizer Inc. rallied to an intraday record after securing wider use of its Covid-19 vaccine, capping a week in which the drugmaker also scored another potential breakthrough with its pill to fight the disease.
The shares rose 1.6% to $52.25 on Friday, topping the previous high of $51.86 set on Aug. 18.